Duobrii in Combination With Biologics
Sponsored by Psoriasis Treatment Center of Central New Jersey
About this study
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks
Where this study is enrolling
- I'm interested
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Who can participate
Inclusion criteria
- ✓1. Male or female adult ≥ 18 years of age;
- ✓2. Diagnosis of chronic plaque-type
- ✓3. Psoriasis affecting 2%-10% BSA
- ✓4. Patient is being treated with biologic therapy for a minimum of 24 weeks
- ✓5. Able and willing to give written informed consent prior to performance of any study-related procedures
Exclusion criteria
- ✕1. Psoriasis affecting ˂2% or \>10% BSA
- ✕2. Patient not receiving a biologic agent, or receiving biologic agent \<24weeks
- ✕3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.
- ✕4. Has previously used DUOBRII
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.